Physician profile
Julia I Ferrell
NPI 1023699311
$2,153.02
in general payments reported to CMS, 2019-2025
15 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $576 · 2024: $532 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,558 · Education: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,558.08 |
| Education | $594.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $580.54 | 2024-2025 | |
| Pfizer INC. | $440.26 | 2023-2025 | |
| Astellas Pharma US INC | $360.30 | 2023-2025 | Xtandi |
| Progenics Pharmaceuticals, INC. | $124.99 | 2025 | |
| Foundation Medicine, INC. | $123.12 | 2023 | |
| Genentech USA, INC. | $108.92 | 2023 | Lunsumio, Polivy |
| Seagen INC. | $84.99 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $83.07 | 2023-2024 | Lynparza, Imfinzi |
| Stemline Therapeutics INC. | $73.95 | 2024 | Orserdu |
| Janssen Biotech, INC. | $72.25 | 2025 | Rybrevant, Carvykti |
| Tolmar, INC. | $28.57 | 2023-2025 | Rubraca, Eligard |
| Amneal Pharmaceuticals LLC | $22.33 | 2023 | Avastin |
| Amgen INC. | $20.59 | 2023 | Kyprolis, Blincyto |
| Pharmaand Gmbh | $14.98 | 2025 | Rubraca |
| Gilead Sciences, INC. | $14.16 | 2023 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Ferrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.